Fundraising FoxCairn Therapeutics
Tucson, US · Founded 2020 · Delaware corporation
Find your way into Cairn Therapeutics
Sign up to see every warm intro you have to Cairn Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cairn Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cairn Therapeutics is a biopharmaceutical company developing oncology treatments intended to address drawbacks of standard chemotherapy such as side effects, low potency, and multidrug resistance. Its lead candidate, CT-262, is based on duocarmycin drug chemistry invented by Dale Boger at Scripps Research.
Founders & leadership
Funding
SEC filings, press & company announcements$3M disclosed across 1 of 2 rounds · 2021–2024
- Undisclosed amountBridge Investment RoundOct 2024Source ↗
▶$3MraisedSep 2021 · 27 investors · PharmaceuticalsRule 506(b)
▶$3MraisedSep 2021 · 27 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Roger RajewskiDirector
- George VielhauerExecutive Officer
- Diarmuid BoranExecutive Officer, Director
- Dale BogerDirector
- W. Scott EvangelistaDirector
- Offering amount
- $7.3M
- Amount sold
- $3M
- Proceeds to insiders
- $300K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
KenaitxKenai Therapeutics develops iPSC-derived cell therapies and gene-modified medicines for neurodegenerative diseases, particularly Parkinson's disease, leveraging induced pluripotent stem cell technology to replace damaged neurons and restore neural function.
Linnaeus TherapeuticsClinical-stage biotech company developing small molecule agents modulating cellular differentiation for cancer and pigmentation disorders.
Marengo TherapeuticsMarengo Therapeutics is a clinical-stage biotech company developing TCR-targeting antibodies that activate specific T cell subsets by targeting Variable β (Vβ) chain variants of the T cell receptor. Its approach aims to modulate the immune system to treat cancer and other diseases.
City TherapeuticsCity Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands. The company aims to expand RNAi therapeutics beyond liver targeting to additional cell and tissue types.
Companies working in the same space as Cairn Therapeutics.
Frequently asked questions
- What does Cairn Therapeutics do?
- Cairn Therapeutics is a biopharmaceutical company developing oncology treatments intended to address drawbacks of standard chemotherapy such as side effects, low potency, and multidrug resistance. Its lead candidate, CT-262, is based on duocarmycin drug chemistry invented by Dale Boger at Scripps Research.
- How much funding has Cairn Therapeutics raised?
- Cairn Therapeutics has disclosed $3M raised across 1 of its 2 known rounds.
- Where is Cairn Therapeutics headquartered?
- Cairn Therapeutics is headquartered in Tucson, US.